middl
east
respiratori
syndrom
coronaviru
merscov
hitherto
unknown
emerg
caus
agent
sever
respiratori
diseas
human
new
coronaviru
first
isol
sputum
patient
suffer
sever
pneumonia
renal
failur
date
merscov
still
caus
diseas
death
human
total
confirm
case
includ
fatal
epidemiolog
data
suggest
merscov
endem
saudi
arabia
account
major
primari
communityacquir
case
mani
primari
case
due
viru
exposur
direct
contact
dromedari
camel
primari
anim
reservoir
merscov
altern
camel
worker
undergo
subclin
infect
suggest
mediat
viru
transmiss
suscept
individu
outbreak
mer
caus
nosocomi
transmiss
health
care
set
merscov
infect
occur
within
arabian
peninsula
ie
saudi
arabia
qatar
unit
arab
emir
howev
mer
case
report
variou
countri
around
world
present
still
rel
littl
known
pathogenesi
merscov
highest
incid
sever
diseas
observ
elderli
immunocompromis
individu
gener
risk
infect
health
care
worker
peopl
close
contact
dromedari
camel
group
therefor
consid
relev
target
popul
prophylact
vaccin
merscov
infect
prevent
mer
world
health
organ
coalit
epidem
prepared
innov
cepi
list
mer
prioriti
target
vaccin
develop
howev
far
candid
vaccin
proceed
beyond
phase
iiia
clinic
test
one
candid
vaccin
base
modifi
vaccinia
viru
ankara
mva
safetytest
replicationdefici
vaccinia
viru
serv
advanc
viral
vector
platform
develop
new
vaccin
infecti
diseas
cancer
review
see
context
still
know
rel
littl
correl
vaccin
induc
protect
merscov
wellknown
virusneutr
antibodi
direct
spike
glycoprotein
protein
correl
protect
immun
coronaviru
infect
gener
sinc
protein
present
cell
surfac
protein
consid
major
antigen
induc
viru
neutral
antibodi
key
immunogen
develop
merscov
candid
vaccin
howev
base
current
knowledg
biolog
hypothes
also
viral
protein
warrant
consider
immunogen
target
virusspecif
antibodi
cell
among
nucleocapsid
protein
n
protein
produc
high
level
infect
cell
propos
use
candid
protein
clinic
diagnosi
coronaviru
n
protein
associ
multipl
function
viru
life
cycl
includ
regul
viral
rna
synthesi
packag
viral
rna
helic
nucleocapsid
virion
assembl
interact
viral
protein
furthermor
sever
report
suggest
sever
acut
respiratori
syndrom
coronaviru
sarscov
n
protein
function
immun
evas
protein
antagonist
host
interferon
respons
recent
overexpress
merscov
n
human
cell
found
link
upregul
antivir
host
gene
express
includ
synthesi
inflammatori
chemokin
despit
possibl
immun
modulatori
activ
sarscov
nspecif
immun
respons
report
longliv
broadli
reactiv
compar
sarscov
sspecif
immun
likewis
curiou
suitabl
merscov
n
protein
serv
vaccin
antigen
n
protein
present
surfac
merscov
particl
predict
express
surfac
membran
mva
infect
cell
hypothes
relev
part
merscov
nspecif
immun
base
cell
respons
reli
process
present
intracellular
antigen
current
littl
inform
merscov
nspecif
immun
respons
includ
vivo
induct
nspecif
cellular
immun
studi
investig
synthesi
deliveri
merscov
n
protein
privileg
antigen
mva
vector
viru
recombin
mva
express
synthet
gene
sequenc
fulllength
merscov
n
mvamersn
prove
genet
stabl
fulli
replicationcompet
chicken
embryo
fibroblast
establish
cell
substrat
mva
vaccin
manufactur
upon
vitro
infect
mvamersn
produc
high
amount
heterolog
protein
detect
merscov
nspecif
antibodi
furthermor
mvamersn
test
experiment
vaccin
balbc
mice
elicit
merscov
nspecif
interferon
produc
cell
use
peptid
librari
cover
whole
merscov
n
polypeptid
identifi
new
restrict
peptid
epitop
merscov
n
balbc
mice
data
highli
relev
assess
n
antigenspecif
immun
respons
wellestablish
merscovbalbc
mous
immunizationchalleng
model
femal
balbc
mice
purchas
charl
river
laboratori
sulzfeld
germani
experiment
work
mice
hous
isol
iso
cage
unit
tecniplast
germani
free
access
food
water
anim
experi
handl
complianc
german
regul
anim
experiment
anim
welfar
act
approv
govern
upper
bavaria
munich
germani
primari
chicken
embryo
fibroblast
cef
prepar
chicken
embryo
spf
egg
valo
cuxhaven
germani
maintain
minimum
essenti
medium
eagl
mem
sigmaaldrich
taufkirchen
germani
contain
heatinactiv
fetal
bovin
serum
fb
sigmaaldrich
taufkirchen
germani
penicillinstreptomycin
sigmaaldrich
taufkirchen
germani
mem
nonessenti
amino
acid
solut
sigmaaldrich
taufkirchen
germani
human
hela
atcc
cell
maintain
mem
contain
fb
penicillinstreptomycin
human
hacat
cl
cell
line
servic
gmbh
eppelheim
germani
cell
cultur
dulbecco
modifi
eagl
medium
sigmaaldrich
taufkirchen
germani
supplement
heatinactiv
fb
hepessolut
sigmaaldrich
taufkirchen
germani
antibiot
describ
cell
maintain
atmospher
cdna
encod
entir
amino
acid
aa
sequenc
aa
merscov
n
protein
silico
modifi
introduc
silent
codon
alter
remov
three
termin
signal
tttttnt
vaccinia
viru
earli
transcript
two
gc
nucleotid
run
origin
merscov
gene
sequenc
human
betacoronaviru
genbank
access
cdna
fragment
gener
dna
synthesi
invitrogen
life
technolog
regensburg
germani
clone
mva
transfer
plasmid
place
merscov
n
gene
sequenc
transcript
control
vaccinia
viru
earlyl
promot
result
mva
vector
plasmid
recombin
mva
gener
use
standard
methodolog
describ
previous
briefli
monolay
nearli
confluent
cef
grown
sixwel
tissu
cultur
plate
sarstedt
germani
infect
nonrecombin
mva
clonal
isol
mva
multipl
infect
moi
min
infect
cef
cell
transfect
plasmid
dna
use
xtremegen
dna
transfect
reagent
lipofectamin
roch
diagnost
penzberg
germani
recommend
manufactur
h
infect
cell
cultur
harvest
recombin
mva
express
merscov
n
protein
clonal
isol
consecut
round
plaqu
purif
cef
screen
transient
coexpress
red
fluoresc
marker
protein
mcherri
qualiti
control
experi
perform
use
standard
methodolog
genet
ident
genet
stabil
recombin
viru
assess
via
polymeras
chain
reaction
pcr
analysi
genom
viral
dna
replic
capac
mva
vector
viru
test
multistep
growth
experi
cef
human
hacat
hela
cell
gener
high
titer
vaccin
prepar
preclin
studi
recombin
mva
amplifi
cef
purifi
ultracentrifug
sucros
cushion
resuspend
mm
trishcl
buffer
ph
store
sucros
purifi
mvamersn
vaccin
prepar
correspond
total
proteintot
dna
content
puriti
profil
mva
candid
vaccin
human
use
confluent
cell
monolay
cef
hacat
cell
infect
moi
recombin
mva
express
merscov
n
protein
noninfect
mock
wildtyp
mvainfect
cell
serv
control
cell
lysat
prepar
differ
time
point
infect
store
total
cell
protein
resolv
electrophoresi
sodium
dodecyl
sulfat
sd
polyacrylamid
gel
sdspage
subsequ
transfer
onto
nitrocellulos
membran
via
electroblot
h
block
phosphat
buffer
salin
pb
buffer
contain
wv
nonfat
dri
milk
vv
deterg
blot
incub
monoclon
mous
antimerscov
nucleocapsid
antibodi
sino
biolog
beij
china
monoclon
rabbit
antimerscov
spike
protein
antibodi
sino
biolog
polyclon
sera
merscov
infect
rabbit
cynomolgu
macaqu
kindli
provid
dr
bart
haagman
erasmu
medic
center
rotterdam
primari
antibodi
wash
pb
blot
incub
antimous
igg
antirabbit
igg
antibodi
protein
conjug
horseradish
peroxidas
cell
signal
technolog
frankfurt
main
germani
wash
blot
develop
use
west
dura
extend
durat
substrat
thermo
fisher
scientif
planegg
gemani
group
femal
balbc
mice
n
immun
twice
within
interv
plaqueformingunit
pfu
recombin
mvamersn
nonrecombin
mva
mva
pb
mock
vaccin
vaccin
given
via
intramuscular
im
intraperiton
ip
rout
use
im
ip
volum
per
inocul
mice
monitor
daili
welfar
potenti
advers
event
immun
day
post
primeboost
immun
anim
sacrif
cervic
disloc
spleen
taken
cell
analysi
cell
immun
monitor
identifi
individu
synthet
peptid
assign
silico
span
entir
merscov
n
protein
sequenc
human
betacoronaviru
genbank
access
peptid
librari
design
contain
peptid
overlap
aa
eightyfour
peptid
could
synthes
thermo
fisher
scientif
organ
twodimension
matrix
peptid
pool
contain
peptid
describ
previous
cell
epitop
map
aa
sequenc
share
peptid
trim
peptid
also
obtain
thermo
fisher
scientif
peptid
dissolv
pb
concentr
mgml
store
use
spleen
harvest
day
post
primeboost
vaccin
splenocyt
prepar
pass
strainer
corn
brand
corn
usa
incub
red
blood
cell
lysi
buffer
sigmaaldrich
taufkirchen
germani
cell
wash
resuspend
rpmi
medium
sigmaaldrich
contain
heat
inactiv
fb
penicillinstreptomycin
splenocyt
process
use
quadromac
kit
miltenyi
biotec
bergisch
gladbach
germani
separ
splenocyt
mac
micro
bead
miltenyi
biotec
bergisch
gladbach
germani
cell
measur
use
elispot
assay
elispot
kit
mous
mabtech
germani
follow
manufactur
instruct
briefli
splenocyt
seed
plate
sarstedt
germani
stimul
peptid
pool
individu
peptid
peptideml
rpmi
medium
h
nonstimul
cell
cell
treat
phorbol
myrist
acet
pma
sigmaaldrich
ionomycin
sigmaaldrich
taufkirchen
germani
mva
peptid
spgaagydl
thermo
fisher
scientif
planegg
germani
serv
neg
posit
control
respect
autom
elispot
plate
reader
softwar
aelvi
eliscan
aelvi
elispot
analysi
softwar
hannov
germani
use
count
analyz
spot
splenocyt
prepar
describ
splenocyt
ad
plate
cellswel
stimul
h
merscov
nspecif
peptid
peptideml
rpmi
medium
presenc
protein
transport
inhibitor
brefeldin
biolegend
san
diego
ca
usa
nonstimul
cell
serv
background
control
cell
stimul
ngml
pma
ngml
ionomycin
peptid
rpmi
medium
use
posit
control
stimul
cell
surfac
antigen
stain
use
peconjug
antimous
clone
biolegend
san
diego
ca
usa
antimous
clone
biolegend
san
diego
ca
usa
fitcconjug
antimous
clone
biolegend
san
diego
ca
usa
antibodi
incub
min
ice
surfacestain
cell
wash
stain
buffer
mac
quanttm
run
buffer
miltenyi
biotec
fix
permeabil
fixat
permwashbuff
biolegend
san
diego
ca
usa
final
stain
intracellular
express
use
apcconjug
antibodi
clone
biolegend
san
diego
ca
usa
min
ice
follow
final
wash
cell
resuspend
stain
buffer
analyz
use
mac
vyb
flow
cytomet
miltenyi
biotec
bergisch
gladbach
germani
statist
analysi
perform
ttest
use
graphpad
prism
version
softwar
graphpad
softwar
san
diego
ca
usa
pvalu
less
consid
statist
signific
recombin
viru
mvamersn
form
cef
infect
mva
transfect
mva
vector
plasmid
figur
mva
dna
sequenc
target
insert
n
gene
sequenc
site
delet
iii
within
mva
genom
clonal
isol
facilit
coproduct
red
fluoresc
report
protein
mcherri
allow
conveni
detect
mvamersn
infect
cell
plaqu
purif
repetit
dna
sequenc
fr
serv
remov
marker
gene
mcherri
genom
final
recombin
viru
initi
intragenom
homolog
recombin
marker
gene
delet
pcr
analysi
confirm
presenc
mvamersn
recombin
virus
cultur
select
final
markerfre
recombin
virus
plaqu
purif
screen
plaqu
without
mcherri
fluoresc
confirm
genet
integr
proper
insert
heterolog
n
gene
sequenc
within
mvamersn
genom
analyz
viral
genom
dna
pcr
use
specif
oligonucleotid
primer
specif
mva
sequenc
adjac
delet
iii
insert
site
figur
addit
pcr
specif
mva
sequenc
within
gene
locu
adjac
major
delet
site
ii
iv
v
vi
serv
control
genet
ident
genom
stabil
mvamersn
figur
data
shown
next
evalu
recombin
viru
mvamersn
multistep
growth
analysi
differ
cell
line
figur
cef
cell
cultur
routin
use
propag
recombin
mva
vaccin
mvamersn
effici
replic
titer
similar
obtain
nonrecombin
mva
contrast
human
cell
line
hacat
hela
prove
nonpermiss
product
viru
growth
confirm
wellpreserv
replic
defici
recombin
mvamersn
cell
mammalian
origin
confirm
synthesi
merscov
n
protein
upon
mvamersn
infect
total
cell
protein
infect
cef
hacat
cell
separ
sdspage
analyz
immunoblot
figur
consist
expect
molecular
mass
merscov
n
protein
readili
detect
kda
polypeptid
use
nspecif
mous
monoclon
antibodi
hour
post
infect
hpi
promin
band
n
protein
visibl
lysat
cell
line
suggest
effici
synthesi
recombin
protein
permiss
nonpermiss
growth
condit
mvamersn
figur
addit
compar
western
blot
analysi
cell
lysat
mvamersn
mvamerss
infect
cef
antigenspecif
mous
monoclon
antibodi
suggest
product
compar
amount
merscov
candid
antigen
figur
observ
line
fact
mvamerss
candid
vector
vaccin
express
merscov
gene
sequenc
use
ident
promot
system
shown
previou
studi
detect
two
merscov
sspecif
protein
band
upon
infect
mvamerss
indic
authent
proteolyt
cleavag
fulllength
glycoprotein
kda
ntermin
kda
domain
ctermin
kda
domain
detect
subunit
follow
use
total
protein
lysat
mvamersn
mvamerss
infect
cef
assess
recognit
merscov
n
antigen
sera
experiment
merscov
infect
anim
western
blot
analysi
sera
infect
rabbit
figur
cynomolgu
monkey
figur
reveal
presenc
antibodi
specif
merscov
n
protein
recognit
merscov
n
protein
least
promin
merscov
antigen
suggest
induct
substanti
nspecif
antibodi
respons
experiment
merscov
infect
cell
respons
coronavirus
known
long
live
mostli
target
conserv
cov
intern
structur
n
protein
howev
inform
merscov
n
antigenspecif
cell
specif
still
limit
thu
aim
first
identifi
n
polypeptidespecif
cell
epitop
balbc
mice
immun
twice
recombin
viru
mvamersn
nonrecombin
mva
control
via
intraperiton
intramuscular
rout
eight
day
final
immun
splenocyt
prepar
purifi
cell
restimul
vitro
overlap
peptid
correspond
n
protein
overlap
peptid
pool
use
twodimension
pooledpeptid
matrix
system
tabl
screen
elispot
stimul
splenocty
mvamersn
immun
mice
peptid
total
peptid
pool
result
detect
produc
cell
background
number
obtain
splenocyt
mock
mvacontrol
vaccin
anim
stimul
peptid
pool
n
n
well
use
vaccinia
viru
posit
peptid
data
shown
show
elev
number
spot
form
cell
sfc
cell
cultur
figur
b
mvamersn
immun
given
ip
im
rout
result
compar
cell
stimulatori
capac
overlap
nspecif
peptid
pool
contrast
peptid
pool
show
minor
stimulatori
activ
exemplifi
peptid
pool
follow
peptid
within
peptid
pool
use
elucid
detail
cell
epitop
specif
subdivid
peptid
four
new
pool
contain
five
peptid
addit
separ
test
two
peptid
share
pool
vaccin
balbc
mice
mvamersn
use
ip
im
inocul
primeboost
regim
splenocyt
prepar
day
eight
last
vaccin
purifi
cell
restimul
subpool
figur
stimul
peptid
pool
activ
minor
level
produc
cell
mean
level
splenocyt
yet
stimul
subpool
reveal
clearli
higher
number
activ
cell
splenocyt
compar
number
produc
cell
induc
ip
im
immun
note
stimul
peptid
qnidayktfpkkekk
ayktfpkkekkqkap
alon
result
detect
substanti
quantiti
produc
cell
mean
level
splenocyt
mice
vaccin
mvamersn
immun
rout
figur
cell
purifi
mice
receiv
nonrecombin
mva
mock
vaccin
pb
produc
follow
stimul
peptid
subpool
peptid
check
specif
peptid
contain
within
subpool
observ
strongli
stimulatori
peptid
part
subpool
wherea
peptid
absent
data
suggest
overlap
peptid
contain
valuabl
antigen
epitop
activ
merscov
nspecif
cell
respons
map
precis
specif
epitop
within
merscov
n
protein
concentr
overlap
peptid
share
peptid
obtain
nine
peptid
tabl
use
peptid
stimul
splenocty
mvamersn
vaccin
mice
obtain
highest
number
produc
cell
peptid
mean
level
splenocyt
peptid
induc
weaker
respons
mean
splenocyt
figur
b
furthermor
test
peptid
monitor
nspecif
cell
respons
ic
fluoresc
activ
cell
sort
fac
analysi
inde
could
detect
signific
number
peptidespecif
cell
induc
activ
mvamersn
primeboost
vaccin
comparison
cell
popul
splenocyt
immun
anim
demonstr
background
level
produc
cell
figur
vaccinia
virusspecif
immunodomin
cell
determin
serv
control
peptid
detect
mvaspecif
cell
figur
avail
appropri
merscovspecif
immun
monitor
tool
prerequisit
success
develop
vaccin
therapeut
approach
develop
tool
hamper
fact
still
know
littl
relev
viral
antigen
overal
pathogenesi
merscov
infect
recent
studi
describ
number
case
asymptomat
merscov
infect
human
rais
question
factor
influenc
clinic
manifest
mer
sinc
asymptomat
mild
clinic
manifest
merscov
infect
often
associ
low
level
seroposit
analysi
merscovspecif
cellular
immun
respons
may
facilit
insight
immun
correl
diseas
prevent
moreov
order
character
pathogenesi
merscov
infect
indispens
monitor
role
virusspecif
cell
anim
model
mer
precis
identifi
antigen
specif
cell
respons
present
studi
identifi
major
histocompat
complex
mhc
haplotyp
restrict
peptid
epitop
merscov
n
protein
stimul
cell
mvamersn
vaccin
balbc
mice
matrix
pool
overlap
peptid
mice
alreadi
use
variou
preclin
studi
establish
merscov
protein
import
vaccin
antigen
induct
viru
neutral
antibodi
moreov
balbc
mice
transduc
human
cell
surfac
receptor
dipeptidyl
peptidas
use
adenoviru
vector
suscept
product
merscov
lung
infect
allow
test
protect
efficaci
merscovspecif
immun
use
merscov
protein
wish
specif
assess
suitabl
mvadeliv
merscov
n
antigen
activ
cellular
immun
respons
mice
gener
n
protein
well
conserv
intern
protein
major
structur
compon
incorpor
viral
rna
within
viral
nucleocapsid
previou
studi
sarscov
n
protein
also
use
candid
antigen
vaccin
develop
experiment
dna
vaccin
effici
induc
sarscov
nspecif
cellular
immun
line
data
recent
studi
mer
patient
demonstr
antibodi
cell
respons
associ
recoveri
merscov
infect
recombin
viru
mvamersn
produc
stabl
amount
merscov
n
antigen
upon
vitro
infect
human
cell
indic
unimpair
express
target
gene
level
viral
late
transcript
use
synthet
vaccinia
virusspecif
promot
moreov
merscov
n
antigen
produc
mvamersn
infect
cell
strongli
recogn
antibodi
experiment
infect
laboratori
anim
suggest
nspecif
immun
respons
potent
activ
upon
merscov
infect
seem
noteworthi
merscov
product
replic
rabbit
viral
load
low
anim
develop
overt
diseas
symptom
howev
haagman
et
al
found
infecti
viru
lung
tissu
rabbit
reveal
presenc
merscov
n
antigen
bronchiolar
epitheli
cell
epitheli
cell
nose
local
n
respiratori
epitheli
cell
may
result
effici
recognit
innat
also
adapt
immun
cell
similar
describ
virus
induc
robust
protect
immun
might
possibl
explan
effici
activ
merscov
nspecif
antibodi
despit
bare
product
merscov
infect
similar
outcom
infect
observ
upon
merscov
infect
cynomolgu
macaqu
relev
nonhuman
primat
model
thu
induct
nspecif
immun
respons
anim
emphas
potenti
use
merscov
n
protein
serv
vaccin
antigen
nevertheless
immunogen
n
requir
character
preclin
model
merscov
infect
addit
induct
merscovspecif
antibodi
merscov
n
protein
hold
promis
effici
activ
virusspecif
cell
respons
detail
studi
character
possibl
role
cell
specif
merscovassoci
immun
pathogenesi
highli
relev
determin
n
peptid
epitop
allow
appropri
mhcrestrict
antigen
present
activ
virusspecif
cell
studi
identifi
new
restrict
cell
epitop
merscov
n
protein
use
matrix
pool
overlap
n
peptid
first
identifi
two
merscov
n
deriv
peptid
qnidayktfpkkekk
ayktfpkkekkqkap
map
peptid
minim
aa
sequenc
yktfpkkekk
repres
decam
peptid
epitop
figur
analysi
merscov
sequenc
reveal
conserv
among
differ
strain
merscov
tabl
avail
epitop
may
allow
detail
experiment
monitor
cellular
immun
respons
induc
mva
base
candid
vaccin
merscov
mous
model
potenti
also
preclin
model
note
restrict
cell
epitop
enabl
character
cell
respons
balbc
mice
serv
wellestablish
merscov
infect
model
follow
adenoviru
vector
mediat
transduct
particular
featur
mer
human
observ
upon
investig
cluster
outbreak
hospit
lack
detect
merscov
neutral
antibodi
patient
confirm
diseas
observ
attribut
emerg
specif
viru
mutant
evad
neutral
antibodi
respons
alreadi
describ
sarscov
thu
futur
use
cellspecif
immun
monitor
might
contribut
detail
understand
mer
pathogenesi
studi
function
merscovspecif
cell
balbc
mous
merscov
lung
infect
model
help
better
estim
role
cellular
immun
vaccin
mediat
protect
merscov
infect
final
mvamersn
vector
viru
gener
studi
prove
stabl
recombin
viru
readili
amplifi
obtain
vaccin
prepar
technic
fulfil
requir
preclin
even
clinic
develop
futur
work
mvamersn
candid
vaccin
help
elucid
potenti
protect
capac
nspecif
immun
respons
merscov
infect
model
contribut
better
understand
mer
vaccineinduc
protect
